LSE · AZN.L
AstraZeneca PLC
£130.52+£2.88 (+2.26%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 17.04% below the high.
Loading market information…
LSE · CTEC.L · GBp
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:48 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
ConvaTec Group Plc’s quoted price sits in the upper half of its reported 52-week range, 6.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
ConvaTec Group Plc’s forward annual dividend is £0.03 per share, paid semi-annual. The forward yield is 1.32% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
ConvaTec Group Plc’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of £0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ConvaTec Group Plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2023 | Mar 6, 2024 | £0.03-33.33% vs estimate | £853.65M-0.92% vs estimate |
|---|
| Q2 2023 | Aug 2, 2023 | £0.05+16.63% vs estimate | £831.56M+2.38% vs estimate |
|---|
| Q4 2022 | Mar 9, 2023 | £0.03-39.49% vs estimate | £838.02M-1.4% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£130.52+£2.88 (+2.26%)
AstraZeneca PLC’s quoted price sits in the upper half of its reported 52-week range, 17.04% below the high.
£18.14-£0.18 (-0.96%)
GSK plc’s quoted price sits in the lower half of its reported 52-week range, 20.51% below the high.
£3.18-£0.56 (-15.05%)
Haleon plc’s quoted price sits in the lower half of its reported 52-week range, 26.73% below the high.
$37.52+$0.41 (+1.1%)
Roivant Sciences Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.72% below the high.
£11.21+£0.02 (+0.13%)
Smith & Nephew plc’s quoted price sits in the lower half of its reported 52-week range, 21.42% below the high.
£2.83-£0.01 (-0.18%)
Advanced Medical Solutions Group plc’s quoted price sits in the upper half of its reported 52-week range, 0.7% below the high.
£0.24+£0.00 (+1.93%)
EKF Diagnostics Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 18.1% below the high.
£0.11+£0.00 (+1.11%)
Creo Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 38.51% below the high.
